---
title: "002900.SZ (002900.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002900.SZ/news.md"
symbol: "002900.SZ"
name: "002900.SZ"
parent: "https://longbridge.com/en/quote/002900.SZ.md"
datetime: "2026-05-21T00:35:46.089Z"
locales:
  - [en](https://longbridge.com/en/quote/002900.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002900.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002900.SZ/news.md)
---

# 002900.SZ (002900.SZ) — Related News

### ["A-Share Focus" Pharmaceutical leader reports good performance, drug stocks boosted, Asymchem hits the upper limit](https://longbridge.com/en/news/284295925.md)
*2026-04-28T02:04:00.000Z*
> Pharmaceutical leader WuXi AppTec released its first-quarter report, with revenue of 12.436 billion yuan, a year-on-year

### [MEDISAN released its first-quarter performance, with a net loss attributable to the parent company of 7.0568 million yuan](https://longbridge.com/en/news/284208571.md)
*2026-04-27T11:49:02.000Z*
> MEDISAN released its first quarter report for 2026, with operating revenue of 229 million yuan, a year-on-year increase 

### [The innovative drug concept has rebounded from the bottom, with MEDISAN hitting the daily limit. Industry insiders: The valuation bottom of the sector has basically been clarified](https://longbridge.com/en/news/282294134.md)
*2026-04-10T03:04:16.000Z*
> On April 10th, the innovative drug concept rebounded, and MEDISAN hit the daily limit. The document No. 9 released by th

### [](https://longbridge.com/en/news/282279794.md)
*2026-04-10T02:44:26.000Z*
> The A-share innovative drug sector saw a short-term surge, with MEDISAN hitting the daily limit, and Haofan Bio, Doru Ph

### [MEDISAN: The raw material drug hydrochloride landiolol production line of its subsidiary has passed the drug GMP compliance inspection](https://longbridge.com/en/news/274617294.md)
*2026-02-03T07:50:22.000Z*
> According to MEDISAN news, recently, the wholly-owned subsidiary of MEDISAN, Lanxi MEDISAN Pharmaceutical Raw Materials,

### [MEDISAN reports a loss exceeding 315 million: How to fight the "turnaround battle" under the impact of the cold wave of centralized procurement + impairment drag? | Financial Report Analysis](https://longbridge.com/en/news/274127949.md)
*2026-01-29T09:44:28.000Z*
> Harbin Sanlian Pharmaceutical released a performance forecast, expecting the total operating revenue for the year 2025 t

### [MEDISAN announced a pre-loss, expecting a net loss attributable to the parent company of 315 million to 375 million yuan for the fiscal year 2025](https://longbridge.com/en/news/273958931.md)
*2026-01-28T08:37:01.000Z*
> MEDISAN expects a net loss attributable to shareholders for the fiscal year 2025 to be between 315 million yuan and 375 

### [MEDISAN: Revenue in 2025 is expected to be 790 million, down 30%, with a net loss forecast of 315-375 million](https://longbridge.com/en/news/273957067.md)
*2026-01-28T08:25:26.000Z*
> MEDISAN expects revenue of 790 million yuan in 2025, a year-on-year decrease of 30%; net profit is expected to be a loss

### [MEDISAN: Wholly-owned subsidiary changes business scope and completes industrial and commercial registration](https://longbridge.com/en/news/269343949.md)
*2025-12-11T07:45:13.000Z*
> MEDISAN announced that its wholly-owned subsidiary Harbin Longjiang Animal Health Biotechnology Co., Ltd. has changed it